Members' Portal
Home
About
Who We Are
Project Team
The Consortium
Donor Support
Countries
Brazil
Cambodia
Ethiopia
Ghana
India
Indonesia
Kenya
Malawi
Mozambique
South Africa
Tanzania
Zimbabwe
Preventing TB
Why Prevention?
Target Populations
Short-Course Preventive Treatments
3HP Dosage and Description
Our Approach
Generating Evidence
Supply & Scale up of 3HP
Civil Society Engagement
Resources
Library
TPT Implementation Tools
COVID-19 Material
Fact Sheets
Publications
Reports
Latest News
Community Engagement Matters
TB & COVID-19 Updates
Frequently Asked Questions
Social Media Toolkits
Videos and Webinars
Useful Links
Members’ Portal
Contact Us
Members' Portal
Home
About
Who We Are
Project Team
The Consortium
Donor Support
Countries
Brazil
Cambodia
Ethiopia
Ghana
India
Indonesia
Kenya
Malawi
Mozambique
South Africa
Tanzania
Zimbabwe
Preventing TB
Why Prevention?
Target Populations
Short-Course Preventive Treatments
3HP Dosage and Description
Our Approach
Generating Evidence
Supply & Scale up of 3HP
Civil Society Engagement
Resources
Library
TPT Implementation Tools
COVID-19 Material
Fact Sheets
Publications
Reports
Latest News
Community Engagement Matters
TB & COVID-19 Updates
Frequently Asked Questions
Social Media Toolkits
Videos and Webinars
Useful Links
Members’ Portal
Contact Us
Useful Links
Market Sectors
COVID-19 and TB
FREQUENTLY ASKED QUESTIONS
dolphin too trial: rifapentine and isoniazid
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy
NTCA PROVIDER GUIDANCE
USING 3HP REGIMEN FOR LTBI
CROI 2019 - Oral abstract
Safety & PK of weekly rifapentine/isoniazid (3HP) in adults with HIV on dolutegravir. 4–7 March 2019
STUDY: dolutegravir with once-weekly isoniazid and rifapentine
Cytokine-mediated systemic adverse drug reactions FOR drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine.
Ship Building Insudtry
Railway
